Biosafety, Biosecurity, and Emerging Biotechnology
Biosafety, Biosecurity, and Emerging Biotechnology
The Biosafety, Biosecurity, and Emerging Biotechnology Policy Division focuses on the development and implementation of policies that promote the responsible conduct and oversight of life sciences research. Specific areas of focus include the NIH Guidelines for Research Involving Recombinant or Synthetic Nucleic Acid Molecules (NIH Guidelines), dual use research of concern (DURC), and the NIH Stem Cell Registry.
Jessica Tucker, Ph.D.
Director
301-451-4431 | jessica.tucker@nih.gov
Biosafety and Recombinant DNA Policy
The Biosafety Recombinant DNA Policy Program manages and evaluates the current biosafety policies for research at institutions that receive NIH support in the US and abroad to help ensure that such research is conducted in accordance with the highest standards to protect the health of researchers, the public and the environment.
Biosecurity Policy
The Biosecurity Policy Program serves as the focal point within NIH for the development and implementation of policies that seek to promote life sciences research while protecting public health and national security by minimizing the potential threats posed by biological pathogens and the potential misuse of information, products, or technologies derived from such research.
Emerging Biotechnology Policy
The Emerging Biotechnology Policy Program is responsible for monitoring and assessing the scientific, ethical, and social implications of certain biotechnologies and, as warranted, monitors the development and integration of those technologies into scientific and clinical practice.